

nr

FILED

APR 24 2018

Judge James F. Hyland

Goodwin Procter LLP

Kate D. Seib, Esq.
(Attorney I.D. No. 019702006)
Jonathan I. Price, Esq.
The New York Times Building
620 8th Avenue
New York, New York 10018
(212) 459-7039
kseib@goodwinlaw.com
jprice@goodwinprocter.com

*Attorneys for Defendants Teva
Pharmaceuticals USA, Inc.; Teva
Parental Medicines, Inc.; Goldline
Laboratories, Inc.; Ivax Pharmaceuticals,
Inc.; Teva Neuroscience, Inc.; and UDL
Laboratories, Inc./Mylan*

Goldberg Segalla

H. Lockwood Miller III, Esq.
(Attorney I.D. No. 03561194)
Goldberg Segalla
301 Carnegie Center, Suite 200
Princeton, NJ 08540-6587
(609) 986-1300
hmiller@goldbergsegalla.com

*Attorneys for Defendants PLIVA, Inc.; Barr
Laboratories, Inc.; Barr Pharmaceuticals,
LLC; Duramed Pharmaceuticals, Inc. (n/k/a
Teva Women's Health, Inc.); Watson
Laboratories, Inc.*

IN RE REGLAN LITIGATION

*Applicable to Charles Nagy,
Case MID-L-010110-14*

**SUPERIOR COURT OF NEW JERSEY
LAW DIVISION: MIDDLESEX COUNTY**

Case No. 289

CIVIL ACTION

MASTER DOCKET: MID-L-10165-14


**ORDER OF DISPOSITION
REGLAN**

As to Defendants Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries, Ltd.; Teva Parental Medicines, Inc.; Goldline Laboratories, Inc.; Ivax Pharmaceuticals, Inc.; Teva Neuroscience, Inc.; and UDL Laboratories, Inc./Mylan; PLIVA, Inc.; Barr Laboratories, Inc.; Barr Pharmaceuticals, LLC; Duramed Pharmaceuticals, Inc. (n/k/a Teva Women's Health, Inc.); PLIVA, d.d.; Watson Laboratories, Inc.; Watson Pharmaceuticals, Inc.; Watson Pharma, Inc. n/k/a Actavis, Inc.; Watson Pharma Private, Ltd.; and Richmond Pharmaceuticals, Inc., **only**

IT IS on this 24 day of April, 2018, ORDERED that all claims against Defendants Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries, Ltd.; Teva Parental Medicines, Inc.; Goldline Laboratories, Inc.; Ivax Pharmaceuticals, Inc.; Teva Neuroscience, Inc.; and UDL Laboratories, Inc./Mylan; and Goldberg Segalla LLP, counsel for Defendants PLIVA, Inc.; Barr Laboratories, Inc.; Barr Pharmaceuticals, LLC; Duramed Pharmaceuticals, Inc. (n/k/a Teva Women's Health, Inc.); PLIVA, d.d.; Watson Laboratories, Inc.; Watson Pharmaceuticals, Inc.; Watson Pharma, Inc. n/k/a Actavis, Inc.; and Watson Pharma Private, Ltd.; and Richmond Pharmaceuticals, Inc., in the action listed above are hereby dismissed with prejudice / disposed due to the following:

- | | |
|---|--|
| <input type="checkbox"/> 04 Partially tried | <input checked="" type="checkbox"/> 23 Settled before trial |
| <input type="checkbox"/> 05 Tried to Completion w/jury | <input type="checkbox"/> 24 Settled while scheduled for trial |
| <input type="checkbox"/> 07 Tried to Completion w/o jury | <input type="checkbox"/> 25 Settled while scheduled for Arbitration |
| <input type="checkbox"/> 08 Default | <input type="checkbox"/> 26 Settled while scheduled for other CDR |
| <input type="checkbox"/> 09 Summary Judgment | <input type="checkbox"/> 27 Settled Friendly Hearing |
| <input checked="" type="checkbox"/> 10 Dismissed w/ prejudice | <input type="checkbox"/> 28 Settled by other CDR |
| <input type="checkbox"/> 12 Dismissed w/o prejudice | <input type="checkbox"/> 29 Settled by Conference with Judge |
| <input type="checkbox"/> 18 Reinstate | <input type="checkbox"/> 82 Default Judgment/Proof Hearing Completed |
| <input type="checkbox"/> 30 Voluntary Dismissal | <input type="checkbox"/> Other (specify) |

IT IS FURTHER ORDERED that plaintiffs' counsel shall circulate a copy of this Order upon all defendants in these matters within seven (7) days of the above date.


James F. Hyland, J.S.C.